Overview

Compare the Impact of Xuezhikang and Atorvastatin on Glucose Metabolism in Dyslipidemia Patients With Prediabetes

Status:
Not yet recruiting

Trial end date:
2023-07-01

Target enrollment:

Participant gender:

Summary

This study is a prospective, randomized, open-label, multi-center trial. The primary objective of the study is to assess whether XZK 1200mg/d, compared to atorvastatin 20mg/d, has a favorable impact on HbA1c levels at 24 weeks of treatment in dyslipidemia patients with prediabetes

Phase:

Phase 4

Details

Lead Sponsor:

Heart Health Research Center

Collaborator:

AstraZeneca

Treatments:

Atorvastatin
Calcium